[go: up one dir, main page]

MX2015004703A - Composiciones cancerigenas inyectables. - Google Patents

Composiciones cancerigenas inyectables.

Info

Publication number
MX2015004703A
MX2015004703A MX2015004703A MX2015004703A MX2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A MX 2015004703 A MX2015004703 A MX 2015004703A
Authority
MX
Mexico
Prior art keywords
therapeutic
cancer cells
cell proliferative
cancer compositions
injectable
Prior art date
Application number
MX2015004703A
Other languages
English (en)
Inventor
Andrew X Chen
Yali Tsai
Original Assignee
Genspera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genspera Inc filed Critical Genspera Inc
Publication of MX2015004703A publication Critical patent/MX2015004703A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se proveen en la presente composiciones de profármacos terapéuticos que pueden ser suministradas a un paciente vía una emulsión inyectable, que comprende un fármaco terapéutico enlazado a un péptido que es eficiente y específicamente escindido por una proteasa seleccionada asociada con un trastorno proliferativo de la célula, incluyendo células cancerígenas, por ejemplo, células cancerígenas de próstata, hígado o pecho, en un paciente. También se proporcionan en la presente métodos para tratar trastornos proliferativos de célula, incluyendo cánceres, con las composiciones de profármacos terapéuticos.
MX2015004703A 2012-10-16 2013-10-14 Composiciones cancerigenas inyectables. MX2015004703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714662P 2012-10-16 2012-10-16
PCT/US2013/064889 WO2014062587A2 (en) 2012-10-16 2013-10-14 Injectable cancer compositions

Publications (1)

Publication Number Publication Date
MX2015004703A true MX2015004703A (es) 2015-10-12

Family

ID=50488875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004703A MX2015004703A (es) 2012-10-16 2013-10-14 Composiciones cancerigenas inyectables.

Country Status (16)

Country Link
US (1) US20150265572A1 (es)
EP (1) EP2908838A4 (es)
JP (1) JP2015534951A (es)
KR (1) KR20150092109A (es)
CN (1) CN104870006A (es)
AU (1) AU2013331518A1 (es)
BR (1) BR112015008421A2 (es)
CA (1) CA2888141A1 (es)
CL (1) CL2015000923A1 (es)
EA (1) EA201590521A1 (es)
HK (1) HK1211203A1 (es)
IL (1) IL238358A0 (es)
MX (1) MX2015004703A (es)
SG (1) SG11201502973YA (es)
WO (1) WO2014062587A2 (es)
ZA (1) ZA201502533B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063194T2 (hu) 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
FR3031678B1 (fr) * 2015-01-19 2019-07-26 Universite Des Sciences Et Technologies De Lille Utilisation conjointe de asp-8adt et d'un inhibiteur d'autophagie dans le traitement de cancer.
EP4267188A1 (en) 2020-12-22 2023-11-01 Cobiores NV Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
US7468354B2 (en) * 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
AU2006301747B2 (en) * 2005-10-12 2011-11-24 Analyticon Discovery Gmbh Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
WO2007087131A2 (en) * 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
US7635682B2 (en) * 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
KR20110036075A (ko) * 2008-07-23 2011-04-06 바라트 쎄럼스 앤드 백신스 리미티드 안정한 주입 가능 수중유형 도세타셀 나노에멀젼
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
CN102939077B (zh) * 2010-06-03 2016-04-06 莱迪杜德制药公司 含有维生素k的纳米乳液组合物

Also Published As

Publication number Publication date
CN104870006A (zh) 2015-08-26
EP2908838A2 (en) 2015-08-26
EP2908838A4 (en) 2016-12-21
KR20150092109A (ko) 2015-08-12
JP2015534951A (ja) 2015-12-07
US20150265572A1 (en) 2015-09-24
EA201590521A1 (ru) 2015-09-30
AU2013331518A1 (en) 2015-04-30
CA2888141A1 (en) 2014-04-24
SG11201502973YA (en) 2015-05-28
IL238358A0 (en) 2015-06-30
WO2014062587A2 (en) 2014-04-24
BR112015008421A2 (pt) 2017-08-08
CL2015000923A1 (es) 2015-08-07
WO2014062587A3 (en) 2014-07-17
ZA201502533B (en) 2017-11-29
HK1211203A1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
MX2016001901A (es) Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
MY166014A (en) Combination therapy methods for treating proliferative diseases
PH12017501576B1 (en) Riluzole prodrugs and their use
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2017007321A (es) Terapias de combinacion.
PH12017550063A1 (en) Combination therapies for treating cancers
NZ749218A (en) Androgen receptor modulator and uses thereof
IN2014DN11099A (es)
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
IN2014MN01945A (es)
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
PH12015502342B1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
IN2014MN01944A (es)
MX2017006076A (es) Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme.
MX2013002155A (es) Compuestos para el tratamiento de cancer.
MX2015004703A (es) Composiciones cancerigenas inyectables.
EA201491352A1 (ru) Способ лечения рака груди
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
MX2014013763A (es) Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor